Diality Inc. today announced that three posters highlighting new data from the first clinical use of the Moda-flx™ Hemodialysis System will be presented during the American Society of Nephrology’s Kidney Week 2025 in Houston, Texas.

“Real-World Urea Clearance and Adequacy with the Moda-flx Hemodialysis System” proves the system’s ability to leverage 600mL/min dialysate flow rate to achieve weekly clearance and ultrafiltration targets from the standard three hemodialysis treatments per week.

“These real-world data demonstrate that the Moda-flx Hemodialysis System consistently delivers dialysis adequacy under typical in-center conditions,” said Aamir Z. Jamal, MD, of California Kidney Associates and principal investigator of the aforementioned study. “The system’s ability to achieve target urea clearance and ultrafiltration goals across a diverse patient population highlights its clinical flexibility and potential to advance high-efficiency dialysis in the in-center setting. We’re encouraged by these early outcomes and look forward to further evaluating performance in broader patient populations.”

“Description of the First Hemodialysis Patients Treated on Moda-flx Hemodialysis System” demonstrates the ability to treat a diverse patient population with a fully integrated reverse osmosis (RO) system and best-in-class clinical flow rates.

“Training Made Easy: Addressing Labor Shortages with Hemodialysis Innovation” showcases data revealing that new clinical users can be trained to use the Moda-flx Hemodialysis System proficiently in under three hours.

“The posters being presented at Kidney Week strongly validate the clinical flexibility of the Moda-flx Hemodialysis System,” said Diality CEO Dr. Osman Khawar. “Our company’s objective is to provide clinicians a single hemodialysis system capable of meeting the variable clinical and usability needs across multiple care settings while reducing the burden of dialysis care. The in-center setting is the most demanding dialysis environment, and our initial data reinforces the system’s strong value proposition for enterprise partners and integrated care organizations.”

The Moda-flx Hemodialysis System is designed to empower kidney care professionals with a wide range of variable flow rates, integrated RO water filtration, and an intuitive, easy-to-use graphical user interface. The system provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated interface. The platform’s compact footprint and mobility enable seamless integration and transportation between dialysis care settings. The Moda-flx Hemodialysis System received U.S. Food and Drug Administration (FDA) clearance for use in professional care settings in August 2024.

Attendees of the ASN Kidney Week 2025 can visit Diality at booth 803.

About Diality

Diality is a medical device company focused on developing solutions to improve lives impacted by kidney disease. The Moda-flx Hemodialysis System is a user-friendly, mobile, and connected hemodialysis platform designed to maximize clinical flexibility by combining prescription capabilities of in-center systems with the ease-of-use of next generation hemodialysis devices. Please visit www.diality.com or find us on LinkedIn to learn more about Diality and The Moda-flx Hemodialysis System.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104758024/en/

"The system’s ability to achieve target urea clearance and ultrafiltration goals across a diverse patient population highlights its clinical flexibility and potential to advance high-efficiency dialysis in the in-center setting."